ArriVent BioPharmaAVBP
AVBP
About: ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Employees: 52
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
4% more funds holding
Funds holding: 80 [Q4 2024] → 83 (+3) [Q1 2025]
1.0% more ownership
Funds ownership: 84.47% [Q4 2024] → 85.46% (+1.0%) [Q1 2025]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 5 (-1) [Q1 2025]
29% less capital invested
Capital invested by funds: $757M [Q4 2024] → $539M (-$218M) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$32
48%
upside
Avg. target
$39
80%
upside
High target
$45
108%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Corinne Johnson | 53%upside $33 | Buy Reinstated | 10 Jul 2025 |
Clear Street Kaveri Pohlman | 48%upside $32 | Buy Initiated | 25 Jun 2025 |
Oppenheimer Jeff Jones | 103%upside $44 | Outperform Maintained | 24 Jun 2025 |
Guggenheim Michael Schmidt | 108%upside $45 | Buy Reiterated | 24 Jun 2025 |
Jones Trading Soumit Roy | 85%upside $40 | Buy Initiated | 20 May 2025 |
Financial journalist opinion
Based on 5 articles about AVBP published over the past 30 days
Negative
Benzinga
1 week ago
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Neutral
GlobeNewsWire
1 week ago
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.
Neutral
GlobeNewsWire
1 week ago
ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. In addition, ArriVent expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of common stock and shares of common stock underlying pre-funded warrants on the same terms and conditions. All of the securities are being offered by ArriVent.
Neutral
GlobeNewsWire
2 weeks ago
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients
Neutral
GlobeNewsWire
3 weeks ago
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event to discuss the firmonertinib clinical program for the treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC) on June 23, 2025 at 8:00 am ET.
Neutral
GlobeNewsWire
1 month ago
ArriVent BioPharma Reports First Quarter 2025 Financial Results
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent Company progress.
Neutral
GlobeNewsWire
2 months ago
ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D.
Neutral
GlobeNewsWire
4 months ago
ArriVent BioPharma Reports Full Year 2024 Financial Results
NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2024, and highlighted recent Company progress.
Neutral
GlobeNewsWire
5 months ago
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan.
Positive
MarketBeat
8 months ago
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Charts implemented using Lightweight Charts™